ライフサイエンスコーパス: initial therapy

1 s because the major benefit results from the initial therapy.

2 atients will not respond to or relapse after initial therapy.

3 spontaneous mutations largely independent of initial therapy.

4 rognostic markers and time from diagnosis to initial therapy.

5 eceived an endothelin receptor antagonist as initial therapy.

6 ave achieved disease control following their initial therapy.

7 eported, we analyzed the outcome of deferred initial therapy.

8 tative patients with cGVHD not responding to initial therapy.

9 se can be made for adding rituximab to RI as initial therapy.

10 essive lymphoma is relapse or nonresponse to initial therapy.

11 ts with stable coronary disease when used as initial therapy.

12 and extended regimens might not be needed in initial therapy.

13 d patients with CML who received imatinib as initial therapy.

14 sporine or tacrolimus remain the standard as initial therapy.

15 ate time period is to measure the effects of initial therapy.

16 No recurrences were noted 12 months after initial therapy.

17 CP, both at baseline and 1 to 2 weeks after initial therapy.

18 and remain tumor free up to 10 months after initial therapy.

19 n the results and the time from diagnosis to initial therapy.

20 nting features, not all of whom responded to initial therapy.

21 mlodipine) or a beta-blocker (metoprolol) as initial therapy.

22 s MP; or intravenous MP alone (1 g/m(2)), as initial therapy.

23 ndications, beta-blockers are recommended as initial therapy.

24 atients (8%) received transplants as part of initial therapy.

25 m diagnosis in 79% of those who responded to initial therapy.

26 prognosis HD treated with varying degrees of initial therapy.

27 levels of these polypeptides and response to initial therapy.

28 andomized patients received helium-oxygen as initial therapy.

29 ts with high-risk ALL and a slow response to initial therapy.

30 ancer recurring 6 months after completion of initial therapy.

31 s with CML who were treated with imatinib as initial therapy.

32 or small lymphocytic lymphoma relapse after initial therapy.

33 r failure, active bleeding at endoscopy, and initial therapy.

34 day 1, but only 5% (2/40) had inappropriate initial therapy.

35 will either not respond to or relapse after initial therapy.

36 or thiazide-type diuretic is recommended as initial therapy.

37 performed approximately 2 months later after initial therapy.

38 omized trials comparing these two options as initial therapy.

39 be administered every 3 to 4 weeks IV during initial therapy.

40 d it is one of the most common components of initial therapy.

41 ubsequent treatment can elucidate effects of initial therapies.

42 To evaluate idelalisib as initial therapy, 64 treatment-naive older patients with

43 ge III or IV follicular lymphoma received as initial therapy a single course of treatment with 131I-t

44 ents received a tyrosine kinase inhibitor as initial therapy, a proportion that increased to 94% for

45 le enzyme levels did not normalize with this initial therapy, additional medications were added in ra

46 d with study site (P = .03), nonadherence to initial therapy (adjusted odds ratio [AOR], 2.94; 95% CI

47 r time, including one-third of patients with initial therapy after 5 to 9 years, and an additional on

48 aluated over 48 months in 4 cohorts based on initial therapy after the index diagnosis: (1) drug mono

49 ariate analysis, advanced-stage, nonsurgical initial therapy, age 50 years or greater at diagnosis, a

50 s, multiple causes of symptoms, jaundice, an initial therapy algorithm, secondary therapy, and defini

51 Inadequate initial therapy also was an important risk factor for re

52 The median time from diagnosis to initial therapy among patients who did not have ZAP-70 w

53 ll help to inform more rational selection of initial therapies and improve the quality of life of pat

54 knowledged before consideration of alternate initial therapies and when comparing results from curren

55 mmarizes the current recommendations for the initial therapy and describes the second and third-line

56 or this mutation may be useful for selecting initial therapy and for follow-up monitoring.

57 This indicates a need for more effective initial therapy and further studies of consolidation the

58 osed with ulcerative colitis to standardised initial therapy and identify predictors of treatment res

59 herapy for vasculitis both as a component of initial therapy and in the management of refractory dise

60 ho achieve a complete or partial response to initial therapy and may do so in similarly responding pa

61 between patients who received FMTv as their initial therapy and patients who received rescue FMTv.

62 A focus on the initial therapy and prophylaxis against chronic graft-ve

63 inical attachment loss > or = 5 mm following initial therapy and radiographic evidence of bone loss.

64 nned for osseous surgery after completion of initial therapy and re-evaluation were enrolled.

65 lysis (compared with peritoneal dialysis) as initial therapy and starting dialysis in more recent yea

66 c who progressed- two (16%) received HSCT as initial therapy and ten (83%) received chemotherapy with

67 gh-risk MM, 73% had a triple-drug regimen as initial therapy, and 18% were in complete response at en

68 ears of age or older, had a slow response to initial therapy, and entered remission at the end of ind

69 Data are emerging regarding their utility as initial therapy, and furthermore, they are been investig

70 , bleomycin, vinblastine, and dacarbazine as initial therapy, and granulocyte colony-stimulating fact

71 eventing disease relapse after diagnosis and initial therapy, and shifting the balance of the host-tu

72 ta regarding demographics, stage, histology, initial therapy, and survival were obtained on all patie

73 lenocytes were recovered >140 days after the initial therapy, and the L-selectinlow memory cell subse

74 and recent developments in the prophylaxis, initial therapy, and therapy for refractory disease are

75 t on the extent of the thrombus, response to initial therapy, and whether thrombophilic factors persi

76 ted with study site (P < .001), adherence to initial therapy (AOR, 0.26; 95% CI, 0.15-0.42; P < .001)

77 es were taken at baseline, 2 weeks after the initial therapy appointment, and 8 weeks after the compl

78 nd proteasome inhibitors-response rates with initial therapy are now between 70% and 100%.

79 creased after 21 days of therapy remained on initial therapy (arm B).

80 f therapy were randomly assigned to continue initial therapy (arm C1) or change to an alternative che

81 This review discusses remodeling, initial therapy based on neurohormonal modulation, and t

82 by dysregulated cyclin D1, responds well to initial therapy but is destined to relapse.

83 cell lymphoma (MCL) usually responds well to initial therapy but is prone to relapses with chemoresis

84 e, 28 to 80 years), were recruited requiring initial therapy by Groupe d'Etude des Lymphomes Follicul

85 ve a median time from diagnosis to requiring initial therapy by standard criteria of approximately 3

86 for eradicating metastatic cancers in which initial therapy, by reducing the size and diversity of t

87 on of treatment resistance to ensure optimal initial therapy choice and regimen succession.

88 Decision-making regarding key questions of initial therapy choice, role of allografting, and change

89 e factors: number of metastases, response to initial therapy, CNS metastases, intrathoracic nodal sta

90 motif-1 had a median time from diagnosis to initial therapy comparable with that of cases without a

91 apies in those who chose sucralfate (61%) as initial therapy compared with overall respondents (26.9%

92 Patients received initial therapy consisting of oral hygiene instructions,

93 Current standard initial therapy consists of amphotericin B (AmB) plus fl

94 h DLBCL and 39% of patients with FL received initial therapy containing rituximab.

95 following were associated with inappropriate initial therapy: direct admission to hospital (not via e

96 ta suggest that in AML, (1) the selection of initial therapy dynamically templates the landscape of a

97 -label study, we compared three regimens for initial therapy: efavirenz plus two NRTIs (efavirenz gro

98 and sustained detumescence and should be the initial therapy employed for patients with SCA and prolo

99 he high expectation of cure (above 80%) with initial therapy, even for advanced disease, is tempered

100 agents or that they should be recommended as initial therapy, except in special situations.

101 or patients with del(17)(p13.1), no standard initial therapy exists, although several options support

102 After initial therapy failed, treatment with vancomycin and ri

103 We report the patterns of initial therapy focusing on the investigation of differe

104 Fortunately, initial therapies for most blood cancers are not highly

105 The standard initial therapy for acute graft-versus-host disease (GVH

106 The addition of MMF to corticosteroids as initial therapy for acute GVHD does not improve GVHD-fre

107 for 14 days, followed by an 8-week taper, as initial therapy for acute GVHD from 1990-2007 at the Uni

108 We conclude that etanercept plus steroids as initial therapy for acute GVHD results in a substantial

109 ids was superior to corticosteroids alone as initial therapy for acute GVHD.

110 Conclusion: SIRT as initial therapy for advanced HCC is noninferior to soraf

111 d be incorporated as a means of intensifying initial therapy for advanced-stage, nonmetastatic HB.

112 to identify the most promising agent(s) for initial therapy for aGVHD.

113 The strategy using IFN with ribavirin as the initial therapy for all patients was associated with a c

114 n chemotherapy and an HER2-targeted agent as initial therapy for all patients with HER2-positive adva

115 f four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transpl

116 Death within 1 year after initial therapy for AML.

117 Initial therapy for AML.

118 tion of ATRA and ATO (with or without GO) as initial therapy for APL was effective and safe and can s

119 high-dose bolus IL-2 should be considered as initial therapy for appropriately selected patients with

120 Anticoagulation is the preferred initial therapy for cancer patients with central venous

121 e plus prednisone versus prednisone alone as initial therapy for chronic GHVD among patients whose pl

122 Adefovir appears to be safe and effective as initial therapy for chronic hepatitis B virus infection

123 of t-MN occurred at a median of 5 years from initial therapy for chronic lymphocytic leukemia, 9 afte

124 closporine or tacrolimus was administered as initial therapy for clinical extensive chronic graft-ver

125 IFN-alpha is now often used as initial therapy for CML, before donor availability is kn

126 PCD should be considered as the initial therapy for culture-positive patients, with surg

127 Although initial therapy for cytomegalovirus (CMV) is usually suc

128 one patient who refused cyclophosphamide as initial therapy for diffuse proliferative nephritis but

129 n (LR), and radiofrequency ablation (RFA) as initial therapy for early hepatocellular carcinoma (HCC)

130 The best initial therapy for elderly patients with chronic lympho

131 investigated the activity of lenalidomide as initial therapy for elderly patients with CLL.

132 omized to antitachycardia pacing or shock as initial therapy for FVT.

133 r regimen of atazanavir (ATV)/RTV+FTC/TDF as initial therapy for HIV-1 infection.

134 d four once-daily antiretroviral regimens as initial therapy for HIV-1 infection: abacavir-lamivudine

135 Limited data compare once-daily options for initial therapy for HIV-1.

136 Survival of 14 patients with relapse after initial therapy for low-risk disease (R1/R2) was 50 +/-

137 of lenalidomide plus rituximab was active as initial therapy for mantle-cell lymphoma.

138 ids and immunosuppression may be a preferred initial therapy for many noninfectious, intermediate, po

139 cessary dialysis and should be emphasized as initial therapy for many patients with end-stage renal d

140 lenalidomide plus dexamethasone (Rev/Dex) as initial therapy for myeloma.

141 y combining thalidomide and dexamethasone as initial therapy for myeloma.

142 s of receiving bevacizumab vs ranibizumab as initial therapy for neovascular AMD among US Medicare be

143 thalidomide plus dexamethasone (thal/dex) as initial therapy for newly diagnosed myeloma.

144 idomide has evidence of clinical activity as initial therapy for older AML patients, and further stud

145 for selective laser trabeculoplasty (SLT) as initial therapy for open-angle glaucoma and ocular hyper

146 inuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA.

147 e) regimens without rituximab maintenance as initial therapy for patients with advanced-stage follicu

148 se results, we are currently studying PCR as initial therapy for patients with CLL.

149 we investigate the efficacy of dasatinib as initial therapy for patients with CML in early chronic p

150 eeks in ART-naive adults supports its use as initial therapy for patients with HIV-1 infection.

151 iptase inhibitors (NRTIs) is recommended for initial therapy for patients with human immunodeficiency

152 this study, the use of MTX and prednisone as initial therapy for patients with WG-related glomerulone

153 ccording to consensus-based recommendations, initial therapy for PMR is prednisone, 12.5 to 25 mg/day

154 Xerosis treatment should be included in the initial therapy for pruritus in all elderly patients.

155 Our data support R-Mono as initial therapy for PTLD arising after renal or liver tr

156 duction in immunosuppression is an effective initial therapy for PTLD.

157 explore reduction in immunosuppression as an initial therapy for PTLD.

158 ntially curative and should be considered as initial therapy for such patients.

159 ies supporting the use of fludarabine as the initial therapy for symptomatic disease.

160 The initial therapy for symptomatic patients with obstructio

161 Plasma exchange is the most effective initial therapy for TTP to date.

162 ow molecular weight heparin is the preferred initial therapy for VTE.

163 Initial therapy for warm antibody autoimmune hemolytic a

164 2) a subclone of the founding clone survived initial therapy, gained additional mutations and expande

165 similar proportions in each group continuing initial therapy had HIV RNA levels of less than 10000 co

166 cs of patients with lupus nephritis ESRD and initial therapies have changed in recent years.

167 eaving the operating room in cases where the initial therapies have had little impact.

168 s of observing asymptomatic patients without initial therapy, ie, "watch and wait." Since the initial

169 opportunity to compare the effectiveness of initial therapies in MCL.

170 Antiarrhythmic medications were used for initial therapy in 154 patients with control of FAT in 7

171 ry NGAL may guide differential diagnosis and initial therapy in allograft recipients with AKI.

172 The use of second-generation TKIs as initial therapy in CML induces high rates of CCyR at ear

173 Purpose Sunitinib is a standard initial therapy in metastatic renal cell carcinoma (mRCC

174 y of the hypomethylating agent decitabine as initial therapy in older patients with AML.

175 ines, the ESC/ESH guideline recommends it as initial therapy in patients at >=140/90 mm Hg.

176 Guidelines for selection of ART as initial therapy in patients with HIV-1 infection do not

177 boosted protease inhibitor is recommended as initial therapy in patients with human immunodeficiency

178 as not achieved with infusional CDE given as initial therapy in patients with poor-risk intermediate-

179 e modulated with antibiotics (AB) as part of initial therapy in PD patients.

180 k (VANISH [Vasopressin vs. Norepinephrine as Initial Therapy in Septic Shock]).

181 Doxorubicin can be omitted as part of initial therapy in the majority of these patients, poten

182 oglobulin (IVIG) and aspirin is the standard initial therapy in the treatment of Kawasaki disease.

183 The clinical success rates of the initial therapy in the two groups were 61 and 84%, respe

184 and deserves further clinical evaluation as initial therapy in these infections.

185 to the other antiretroviral regimens used as initial therapy in this study.

186 CLL cells, the median time from diagnosis to initial therapy in those who had an unmutated IgV(H) gen

187 a also suggest that VRC should be avoided as initial therapy in unstable patients with invasive candi

188 lls, preferably within the first 4 cycles of initial therapy, in patients treated with novel agents a

189 evaluation 4-6 weeks after the completion of initial therapy, in which the primary outcome of complet

190 Initial therapy included combination chemotherapy and su

191 Reasons for no initial therapy included: physician choice (n = 20), lar

192 Initial therapy includes surgery and adjuvant therapy.

193 rally similar vertical bony defects received initial therapy including scaling and root planing follo

194 odine, or surgery, but whether the choice of initial therapy influences long-term outcomes is uncerta

195 In this multicenter trial we compared initial therapy involving four-drug regimens containing

196 Initial therapy is applied to reduce population size and

197 Initial therapy is deferred in a small subset of patient

198 For prolactinomas, initial therapy is generally dopamine agonists.

199 For all other pituitary adenomas, initial therapy is generally transsphenoidal surgery wit

200 myeloma who received this class of drugs for initial therapy is unknown.

201 CL-1/BCL-XL and (2) appropriate selection of initial therapy may delay or altogether forestall the ac

202 as improved over time and that the choice of initial therapy may matter.

203 rty-one patients treated with pentostatin as initial therapy (n = 154) or who crossed over after fail

204 The concept of periodontal reevaluation of initial therapy needs to be revisited.

205 linical presentation, diagnostic workup, and initial therapy of 2 of these patients.

206 teroids and daclizumab should not be used as initial therapy of acute GVHD.

207 t of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia (AML) and (2)

208 es and the wild green variety is used in the initial therapy of benign prostatic hyperplasia (BPH), g

209 mia (CML) and are now widely accepted as the initial therapy of choice in this disease, supplanting i

210 recently approved with chlorambucil for the initial therapy of chronic lymphocytic leukemia (CLL).

211 e randomized intergroup phase 3 E2997 trial, initial therapy of chronic lymphocytic leukemia with flu

212 patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia.

213 r both of these 'second-generation' TKIs for initial therapy of CML.

214 ted (90)Y-ibritumomab tiuxetan ((90)Y-IT) as initial therapy of follicular lymphoma (FL).

215 Initial therapy of hypertension with beta-blockers is no

216 chronic lymphocytic leukemia treated with an initial therapy of lenalidomide.

217 Initial therapy of metastatic breast cancer with paclita

218 ilability of drugs and drug combinations for initial therapy of myeloma as well as maintenance approa

219 aim is to review current recommendations for initial therapy of patients with early chronic phasechro

220 For initial therapy of patients with liver disease, we use a

221 For initial therapy of patients with neurologic disease we u

222 d empirical ATP (n=313) or shock (n=321)-for initial therapy of spontaneous FVT.

223 ne the impact of HCA cSSTI and inappropriate initial therapy on outcomes.

224 (1) had a new diagnosis and were planned for initial therapy or (2) had developed acquired resistance

225 Disease progression may occur during initial therapy or after complete eradication in a small

226 st cancer includes an aromatase inhibitor as initial therapy or after treatment with tamoxifen.

227 an be effectively treated with a diuretic as initial therapy or as part of a combination regimen.

228 on alfa-2b alone or with ribavirin either as initial therapy or for interferon relapse.

229 r secondary open angle glaucomas, both as an initial therapy or in conjunction with hypotensive medic

230 ested with the aim of decreasing the cost of initial therapy or to improve compliance, but abbreviate

231 strogen tamoxifen will either not respond to initial therapy or will develop drug resistance.

232 receiving iodine I(131) tositumomab as their initial therapy (P = .011 compared with previously treat

233 an altered local inflammatory response after initial therapy, perhaps symptomatic of colonization by

234 refore, knowledge of RER status could affect initial therapy, postoperative chemotherapy, and follow-

235 Achievement of VGPR or better with this initial therapy predicted longer PFS, regardless of the

236 atient received oral hygiene instruction and initial therapy prior to surgery.

237 arly after 9 months to the limited amount of initial therapy provided.

238 m outcomes were compared on the basis of the initial therapy received.

239 b- and imatinib-treated patients remained on initial therapy, respectively.

240 MAPK regulates myosin II activity, but after initial therapy response, drug-resistant clones restore

241 various stages of myeloma therapy, including initial therapy resulting in improvement of disease cont

242 Initial therapy should be amoxicillin in a high dosage (

243 Despite favorable responses to initial therapy, small-cell lung cancer (SCLC) relapse o

244 After initial therapy, smokers exhibited significantly less re

245 therapy (seizure density), poor response to initial therapy, some epilepsy syndromes.

246 acute myeloid leukemia (AML) who respond to initial therapy subsequently relapse.

247 lamic brain regions in glioma patients after initial therapy, suggesting treatment effects on the ser

248 argely weighted to maintenance as opposed to initial therapy, switching from more potent to less expe

249 data suggest the same for patients receiving initial therapies that did not contain cytarabine.

250 A secondary outcome was time to receipt of initial therapy that was evaluated using Cox shared frai

251 ervational period' (excluding extractions at initial therapy), the average tooth loss for AgP was 0.0

252 symptoms, and despite the early induction of initial therapy, the symptoms became worse.

253 om study entry until either reinstitution of initial therapy, therapy with a second agent, or death).

254 If patients had a good response to initial therapy, they proceeded to consolidation therapy

255 ) of enteric fever cases were not covered by initial therapy; this was highest in Pakistan (50%) as m

256 Use of imaging after initial therapy to assess for recurrence and to plan sal

257 amine agonists can be used as an alternative initial therapy to delay the onset of motor complication

258 ased oxygen carriers can adequately serve as initial therapy to maintain tissue oxygen delivery while

259 ); and also did a second randomisation after initial therapy to maintenance chemotherapy (fluorouraci

260 nd to determine the best time interval after initial therapy to perform a reevaluation based on class

261 have a relapse in symptoms after successful initial therapy, usually in the first few weeks after tr

262 recurrent disease is similar to that of the initial therapy; visible recurrent nodular lesions requi

263 urvival of patients who received imatinib as initial therapy was 89% at 60 months.

264 ilure to achieve control of AD symptoms with initial therapy was associated with a higher risk of rel

265 Initial therapy was designated "appropriate" versus "ina

266 atment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in

267 mporaneous patients with GVHD (n = 99) whose initial therapy was steroids alone.

268 Cryoballoon ablation as initial therapy was superior to drug therapy for the pre

269 , the objective response rates observed with initial therapy were 32% for arm 1, 24% for arm 2, and 1

270 Patients who sustained remission after initial therapy were distinguished only by a lower serum

271 were in their first relapse or refractory to initial therapy were randomly assigned to one of two sal

272 alis) and Tannerella forsythia who completed initial therapy were randomly assigned to receive SubGPA

273 00 for relapse of GCT more than 2 years from initial therapy were reviewed.

274 ), Q-wave infarction, in-hospital death, and initial therapy were studied.

275 ad reduction of immunosuppression as part of initial therapy, whereas 59 (74%) of 80 patients receive

276 All patients underwent initial therapy, which included scaling and root planing

277 and plaque index (PI) were measured prior to initial therapy, which involved oral hygiene instruction

278 Initial therapies with other azoles were excluded.

279 ent recommendations for hypertension include initial therapy with a diuretic or beta-adrenergic block

280 arly clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is

281 Initial therapy with dose-adjusted intravenous unfractio

282 nic lymphocytic leukemia (CLL) have received initial therapy with fludarabine as a single agent or fl

283 In patients with chronic hepatitis C, initial therapy with interferon and ribavirin was more e

284 tification systems among patients undergoing initial therapy with lenalidomide in the context of a ph

285 We studied the outcome after initial therapy with lenalidomide-dexamethasone among 10

286 rubicin, vincristine, and prednisone (CHOP), initial therapy with more dose-intense regimens resulted

287 In patients with early seropositive RA, initial therapy with MTX plus doxycycline was superior (

288 etwork of Pediatric MS Centers, who received initial therapy with newer (fingolimod, dimethyl fumarat

289 All patients received initial therapy with open-label enoxaparin or unfraction

290 re intensive schedules of the drugs used for initial therapy with or without haemopoietic stem cell t

291 with chronic hepatitis C fail to respond to initial therapy with pegylated interferon (PEG-IFN) and

292 r primary carcinoma of the peritoneum; prior initial therapy with platinum/paclitaxel; and failure to

293 rvational data, suggest that the benefits of initial therapy with rituximab in a heterogeneous group

294 cohorts with less than a partial response to initial therapy with single-agent CP-751,871.

295 ors, including those that had recurred after initial therapy with temozolomide.

296 We conducted a randomized trial of initial therapy with zidovudine and lamivudine plus eith

297 Several regimens are acceptable as initial therapy, with tenofovir/emtricitabine/efavirenz

298 logy visits declined over time regardless of initial therapy, with the greatest decrease among the un

299 ected that patients relapsing after inferior initial therapy would have a higher retrieval rate than

300 Corticosteroids remain the standard initial therapy, yet only 25% to 41% of patients complet